Array Biopharma (ARRY) Reports In-Line Q1 EPS
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $4.98 -1.39%
Financial Fact:
Total operating expenses: 63.27M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Total operating expenses: 63.27M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Array Biopharma (NASDAQ: ARRY) reported Q1 EPS of ($0.22), in-line with the analyst estimate of ($0.22). Revenue for the quarter came in at $29.7 million versus the consensus estimate of $33.28 million.
For earnings history and earnings-related data on Array Biopharma (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c
- Barclays Upgrades Schott Pharma AG (1SXP:GR) to Overweight
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
